EQT将从Corza Medical收购TachoSil®生物外科业务-动脉网

EQT to acquire the TachoSil® biosurgery business from Corza Medical

CISION 等信源发布 2026-07-07 14:49



可切换为仅中文







EQT to acquire Corza Biosurgery, a premier biosurgery business built around TachoSil, a leading hemostat and sealant patch used across a wide range of surgical specialties

EQT 将收购 Corza Biosurgery，这是一家领先的生物外科企业，其核心产品为 TachoSil——一款广泛应用于多种外科领域的领先止血密封贴片。

TachoSil supports improved surgical outcomes through rapid bleeding control and tissue sealing, and is backed by extensive clinical evidence, health-economic data and surgeon advocacy

TachoSil通过快速止血和组织封闭支持改善手术结果，并有广泛的临床证据、卫生经济学数据和外科医生的倡导作为支撑。

EQT will support TachoSil and its management team, led by Thierry Leclercq, in their next phase of growth by investing in commercial acceleration, indication and geographic expansion, innovation, and by building out a broader biosurgery platform through M&A

EQT 将通过投资以加速商业化、拓展适应症及地理市场、推动创新，并通过并购打造更广泛的生物外科平台，支持 TachoSil 及其由 Thierry Leclercq 领导的管理团队进入下一阶段的成长。

STOCKHOLM

斯德哥尔摩

，

July 7, 2026

2026年7月7日

/PRNewswire/ -- EQT is pleased to announce that EQT X ('EQT') has agreed to acquire Corza Biosurgery (the 'Company') from Corza Medical, comprising TachoSil

/美通社/ -- EQT欣然宣布，EQT X（“EQT”）已同意从Corza Medical收购Corza Biosurgery（“公司”），其中包括TachoSil

, a leading dual-action active biologic patch that both controls bleeding and seals tissue during surgery. EQT also announced that Sheri McCoy, former Chair of Johnson & Johnson's Surgical Care Group, will serve as Board Chair of the standalone company upon closing of the transaction.

，这是一种领先的双效活性生物贴片，可在手术过程中同时控制出血并封闭组织。EQT还宣布，强生公司外科护理集团前主席谢丽·麦考伊将在交易完成后担任该独立公司的董事会主席。

Corza Biosurgery is a pioneer in complex surgical biologics, with a proven 20+ year track record of highly specialized manufacturing at its facility in Linz, Austria. Used by surgeons in over 50 countries across a broad range of surgical specialties, including cardiovascular, neuro, hepatic and thoracic, the TachoSil patch has an established reputation based on its efficacy, safety profile, and extensive evidence base, including more than 540 clinical trial publications.

Corza Biosurgery 是复杂外科生物制品领域的先驱，其在奥地利林茨的工厂拥有经过验证的20多年高度专业化制造经验。TachoSil 补片被全球50多个国家的 surgeons 广泛应用于心血管、神经、肝脏和胸外科等多个外科专科领域，凭借其疗效、安全性以及包括540余篇临床试验发表文献在内的广泛证据基础，建立了良好的声誉。

The Company employs approximately 400 people worldwide. .

该公司在全球雇佣了大约400名员工。

As surgical procedures become increasingly complex, healthcare providers are placing even greater emphasis on improving patient outcomes, reducing complications, and increasing efficiency. TachoSil addresses these priorities by helping surgeons achieve rapid hemostasis and effective tissue sealing in complex and high-stakes intraoperative situations, supporting shorter procedure times, minimizing adverse surgical events, and accelerating patient recovery.

随着外科手术日益复杂，医疗保健提供者更加重视改善患者预后、减少并发症并提高效率。TachoSil通过帮助外科医生在复杂且高风险的术中情况下实现快速止血和有效组织封闭，从而缩短手术时间、最大限度地减少不良手术事件并加速患者康复，以此应对这些优先事项。

With surgical volumes rising on the back of aging populations, increasing prevalence of chronic disease, and ongoing advances in surgical techniques, EQT believes TachoSil is well-positioned to continue expanding its impact on patients and healthcare providers worldwide. .

随着人口老龄化、慢性病患病率上升以及手术技术的持续进步，手术量不断增长，EQT认为TachoSil有望继续扩大其在全球患者和医疗保健提供者中的影响力。

Leveraging its healthcare expertise and global network, EQT will support the Company in its next phase of growth with significant investments in commercial capabilities, innovation and a globally scaled organization. Together with management, EQT will focus on accelerating growth in the U.S. – including through commercial and indication expansions – and broadening adoption across other underpenetrated markets.

依托其在医疗健康领域的专业专长和全球网络，EQT 将通过在商业能力、创新以及全球化规模组织方面进行重大投资，支持公司进入下一阶段的成长。EQT 将与管理层携手，重点加速在美国市场的增长——包括通过商业拓展和适应症扩展——并扩大在其他渗透率较低市场的采纳与应用。

EQT also sees opportunities to build a broader biosurgery platform through partnerships and complementary acquisitions. .

EQT还希望通过合作和互补性收购，构建更广泛的生物外科平台。

Ethan Waxman, Partner at EQT, said: 'TachoSil has a unique clinical value proposition that improves patient outcomes across critical surgical procedures around the world, and is backed by strong physician preference and extensive clinical evidence. We are deeply impressed by the dedication of the Corza Biosurgery team and look forward to partnering with them to expand access globally, invest in growth, and further strengthen the Company's position as a leading biosurgery platform.' .

EQT合伙人伊桑·瓦克斯曼（Ethan Waxman）表示：“TachoSil拥有独特的临床价值主张，能够改善全球关键手术中的患者预后，并得到医生强烈偏好和广泛临床证据的支持。我们对Corza Biosurgery团队的敬业精神深感钦佩，并期待与他们合作，扩大全球市场覆盖，投资增长，并进一步巩固该公司作为领先生物外科平台的地位。”

'We are excited to partner with EQT during a pivotal moment for TachoSil,' said Thierry Leclercq, President of Corza Biosurgery. 'EQT's healthcare expertise, operational resources, and commitment to long-term growth align perfectly with our vision to expand access to TachoSil globally and advance innovation.' .

“在TachoSil发展的关键时期，我们很高兴能与EQT合作。”Corza Biosurgery总裁Thierry Leclercq表示，“EQT在医疗健康领域的专业知识、运营资源以及对长期增长的承诺，与我们在全球范围内扩大TachoSil可及性并推动创新的愿景高度契合。”

The transaction is subject to customary conditions and approvals. It is expected to close during Q4 2026. Piper Sandler acted as financial advisor to EQT and Latham & Watkins LLP provided legal counsel.

该交易须满足惯例条件并获得相关批准，预计将于2026年第四季度完成。Piper Sandler担任EQT的财务顾问，Latham & Watkins LLP提供法律顾问服务。

With this transaction, EQT X is expected to be 80-85 percent invested (including closed and/or signed investments, announced public offers, if applicable, and less any expected syndication).

通过此次交易，EQT X 的预计投资比例将达到 80% 至 85%（包括已交割和/或已签署的投资、已公布的公开要约（如适用），并扣除任何预期的银团分摊部分）。

Contact

联系

EQT Press Office,

EQT 新闻办公室，

[email protected]

This information was brought to you by Cision

本信息由 Cision 提供

http://news.cision.com

https://news.cision.com/eqt/r/eqt-to-acquire-the-tachosil--biosurgery-business-from-corza-medical,c4371632

The following files are available for download:

以下文件可供下载：